Mer­ck crush­es Keynote-407 study in front­line lung can­cer, hit­ting co-pri­maries and set­ting up an­oth­er quick OK

Con­tin­u­ing its march to the to­tal dom­i­na­tion of front­line lung can­cer treat­ment, Mer­ck $MRK this morn­ing an­nounced that its Phase III Keynote-407 study hit both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER